Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II

Inclusion Criteria: * Aged ≥ 18 years or older at time of screening on FWS) as determined by in-clinic assessments by both the investigator and the subject(where: 0= 'none', 1= 'mild', 2= 'moderate', 3= 'severe'). * Subject has a stable medical condition with no uncontrolled systemic disease. * Female subjects of childbearing potential must test negative for pregnancy and agree to use effective birth control during the course of the study. * Subjects who wear glasses must be able to adequately self-assess the severity of their glabellar lines (according to the FWS), without glasses obstructing the forehead area. * The moderate to severe glabellar lines have an important psychological impact on the subject, as indicated by scores \>0 on either the Emotional or the Social Functioning subscale of the modified Skindex-16 (GL-QoL). Exclusion Criteria: * Previous treatment with any serotype of botulinum toxin for any indication within the 12 months prior to screening, or any planned treatment with botulinum toxin of any serotype for any reason during the trial (other than the investigational treatment). * Known hypersensitivity to the study medication or its excipients. * Any medical condition that may place the subject at increased risk due to exposure to botulinum toxin, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, profound atrophy or weakness in the target muscles, or any other condition (at the investigator's discretion) that …